Engineered viral vectors (adeno, vaccinia/MVA, lentivirus, AAV) that deliver neoantigen payloads — including Nouscom's and Transgene's programs.
Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC. Adjuvant treatment with the individualized, viral vector–based neoantigen vaccine TG4050 was safe and induced durable neoantigen-specific CD8-positiv…
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected, HPV-negative HNSCC. TG4050, a modified Vaccinia Ankara (MVA) viral vector–based individualized neoantigen therapeutic vaccine encoding up to 30 …
2026 Half-Year Results and Business Update myvac® - Expanding potential across solid tumors through viral vector, AI driven neoantigen selection, and scalable cell-line manufacturing TG4050 - First Individualized Neoantigen Therapeutic Vaccine (INTV) from the myvac® platform adva…
Nouscom, a clinical-stage biotech headquartered in Basel, Switzerland, announced receipt of US FDA Fast Track Designation for NOUS-209, a viral vector-based, off-the-shelf neoantigen cancer vaccine, for the prevention of Lynch Syndrome (LS)-associated cancers in carriers with gen…